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Abstract
Background
The role of serum TSH concentrations as a predictor of malignancy of thyroid nodule
remains unclear.
Objective
To prospectively evaluate the usefulness of serum TSH levels as a predictor of malignancy
in thyroid nodules.
Methods
Patients with thyroid nodule(s) who underwent fine-needle aspiration biopsy under ultraso-
nographic guidance in a tertiary, university-based hospital were consecutively evaluated.
Patients with known thyroid cancer and/or patients receiving thyroid medication were
excluded. Serum TSH levels were measured by two differents methodologies, chemilumi-
nescent (CLIA) and electrochemiluminscent immunoassay (ECLIA). Anatomopathological
exam of tissue samples obtained at thyroidectomy was considered the gold standard for the
diagnosis of thyroid cancer.
Results
A total of 615 patients participated in the study. The mean age was 55.9±14.7 years, and 544
(88.5%) were female. The median TSH values were 1.48 and 1.55 μU/mL, using CLIA and
ECLIA, respectively. One-hundred-sixty patients underwent thyroidectomy and the final diag-
noses were malignant in 47(29.4%) patients. TSH levels were higher in patients with malig-
nant than in those with benign nodules in both TSH assays: 2.25 vs. 1.50; P = 0.04 (CLIA) and
2.33 vs. 1.27; P = 0.03 (ECLIA). Further analysis using binary logistic regression identified ele-
vated TSH levels, a family history of thyroid cancer, the presence of microcalcifications, and
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solitary nodule on US as independent risk factors for malignancy in patients with thyroid nod-
ules. Additional analyses using TSH levels as a categorical variable, defined by ROC curve
analysis, showed that the risk of malignancy was approximately 3-fold higher in patients with
TSH levels2.26 μU/mL than in patients with lower TSH levels (P = 0.00).
Conclusions
Higher serum TSH levels are associated with an increased risk of thyroid cancer in patients
with thyroid nodules. Using TSH levels as an adjunctive diagnostic test for stratifying the risk
of malignancy associated with a thyroid nodule may help on defining the best therapeutic
approaches.
Introduction
Palpable thyroid nodules are a common disorder detected in 4–7% of adults in the general
population and in 19–67% of patients who undergo high-resolution ultrasound [1–5]. In con-
trast, thyroid cancer is rare. However, in most cases, thyroid carcinoma presents clinically as a
nodule (solitary or in a multinodular gland) that is indistinguishable from benign neoplasia.
The challenge for clinicians, therefore, is to distinguish malignant (5–10%) from benign thy-
roid nodules[4,5]. Of note, the last National Cancer Institute State Cancer Profile has shown
that the incidence of thyroid cancer is rising faster than that of any other malignant neoplasia
[6].
Fine-needle aspiration biopsy (FNAB) is the gold standard for evaluating patients with thy-
roid nodules, and it is currently the most reliable diagnostic technique for evaluating thyroid
nodules under ultrasound guidance[5,7]. Diagnostic results are obtained in most cases, as
inadequate specimens (nondiagnostic or unsatisfactory) occur in only 5–10% of cases. How-
ever, FNAB cannot reliably rule out cancer in 20–30% of nodules, reported as indeterminate
for malignancy [8–10] The Bethesda classification [11] recognizes three specific cytological
diagnoses characterized by indeterminate cytology. The predicted probability of cancer is
5–10% in Bethesda III patients, 20–30% in Bethesda IV patients, and 50–75% in Bethesda V
patients, but variability has been noted at different centers [8,10] and most patients with inde-
terminate cytology undergo surgery to establish the histopathologic diagnosis. However, only
10–20% of the thyroid nodules with indeterminate cytology (Bethesda III and IV) are malig-
nant[8,12–14]. New diagnostic approaches based on thyroid cancer molecular biomarkers
have recently been studied, and some are already introduced in clinical settings. Currently, the
most successful panels testing for mutations in thyroid FNAB samples are those testing for
BRAF and RAS point mutations and RET/PTC and PAX8/PPARγ rearrangements, as well as
TRK rearrangements [15, 16]. Although the use of these molecular tools have been validated in
some studies, these tests are expensive (and not cost-effectivity depending of thyroid cancer
prevalence), and their impact on patient management remains debatable[17–20].
The role of TSH as a predictor of thyroid nodule malignancy has been evaluated by several
studies in the last years. Since Boelaert has reported parallel increases in malignancy risk and
serum TSH levels[21], several other authors have investigated the relationship between serum
TSH levels and thyroid cancer with conflicting results[22–24]. A recent meta-analysis found a
positive association between higher serum TSH levels and increased risk of thyroid cancer[25].
However, the analysis had some limitations, as all of its included studies were cross-sectional,
and the vast majority was retrospective (only two prospective studies). In contrast, the EPIC
TSH levels and thyroid nodules
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study, which is based on a huge European cohort, demonstrated a negative association
between TSH levels and thyroid cancer risk[26]. Although the EPIC study is a large prospec-
tive study, it is a case-control study featuring control subjects who were chosen from a group
of cancer-free participants constituting the EPIC cohort (healthy population), thus, which may
limit its conclusions.
Here, we aimed to evaluate the role of serum TSH levels as predictor of thyroid nodule
malignancy in a cohort of patients with thyroid nodules in a tertiary, university-based hospital.
Materials and methods
Consecutive patients with thyroid nodule(s) who underwent FNAB under ultrasonographic
guidance (US-FNAB) between 2012 and March of 2016 in the Thyroid Unit of the Hospital de
Clı´nicas de Porto Alegre, a tertiary, university-based hospital, were prospectively evaluated.
The geographical area of the study is iodine sufficient[27]. All patients were referred for evalu-
ation of thyroid nodules and underwent a complete history and physical examination. Patients
with known thyroid cancer and/or patients receiving thyroid-related medication were
excluded. TSH levels, ultrasound characteristics of the nodules, demographic and clinical data
were compared in patients with benign and malignant thyroid nodule. The project was
approved by the Research Ethics Committee of the Hospital de Clı´nicas de Porto Alegre
(GPPG 140538). The study was conducted in accordance with the ethical standards of the local
institutional, national research committee and with the Helsinki declaration. The local institu-
tional and national research committee did not request informed consent, as the data were
analyzed anonymously and the assistance of patients follow routine clinical indications.
Laboratory evaluation
Serum TSH levels were measured by two different methodologies, chemiluminescent immu-
noassay (CLIA) (ADVIA Centaur XP; Siemens, Tarrytown, NY), with interassay coefficient of
variation of 5.3% over the range 0.35–5.50 μU/mL, were used until November 2014. After that,
TSH levels were measured by electrochemiluminscent immunoassay (ECLIA) (Roche Diag-
no´stica, São Paulo, Brasil), with interassay coefficient of variation of 3.11%, reference values:
0.27–4.20 uUI/mL. The thyroid peroxidase antibodies (TPO-Ab) was evaluated by chemilumi-
nescent immunoassay (IMMULITE Systems, Siemens Healthcare Diagnostics, Tarrytown,
NY), reference value inferior of 34.0UI/mL.
Ultrasound examination
All patients underwent thyroid US-FNAB, which was performed by the same radiologist using
a high-resolution ALOKA ultrasound device with a 7.5 MHz linear transducer (Tokyo, Japan).
The number of thyroid nodules, as well as sizes, US characteristics (echogenicity, the presence
of microcalcification, halos, contours, and shape), and the presence of cervical lymphadenopa-
thy were documented in the medical records of all patients.
FNAB, cytological and histological diagnosis
FNA and cyto-cell block testing. US-FNA was performed with a disposable needle (21G) con-
nected to a 10 ml disposable syringe[14]. Multidirectional aspiration was performed in domi-
nant nodules in patients with multinodular goiters and/or suspicious nodules on
ultrasonography[5,7]. Rapid on-site evaluations of all fine-needle aspiration specimens were
performed to determine the adequacy of each specimen. A thyroid FNA specimen was consid-
ered satisfactory if at least 6 groups of follicular cells were present, and each group comprised
TSH levels and thyroid nodules
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at least 10 cells. Immediate on-site reaspiration was performed in cases in which specimens
considered inadequate for diagnosis were obtained. Six cytology slides were prepared for each
patient, four of which were air-dried and immediately stained via the May Gru¨mwald Giemsa
technique. The other two slides were immediately fixed in ethanol 96˚ and subsequently
stained via the Papanicolaou technique. The residual hemorrhagic aspirated in the syringe and
needle was fixed in 10% formalin. Then, the aspirated material was centrifuged, paraffin-
embedded (cell block), sectioned and stained with hematoxylin and eosin to serve as a comple-
mentary diagnostic specimen to the FNA specimen. A sample was considered viable if it con-
tained a sufficient number of cells with intact morphology (60 cells from at least 6 groups of 10
follicular cells).
Two independent pathologists reviewed the cytological and histological slides of each case
together and assigned the samples to a final diagnostic category. Cytological aspirate adequacy
was defined according to the recommendations of the Papanicolaou Society of Cytopathology
Task Force on Standards of Practice (1996), and the cytological results were classified into the
following 6 diagnostic categories according to the criteria of the Bethesda System for Cytologi-
cal Classification of Thyroid Nodules: 1) non-diagnostic or unsatisfactory, 2) benign, 3) atypia
of undetermined significance, 4) a follicular neoplasm or suspicious for a follicular neoplasm,
5) suspicious for malignancy and 6) malignant.
Cell-block slides were reviewed for the presence of cellular elements and classified into the
following two categories: 1) diagnostic and 2) non-diagnostic. Cell-block US-FNBA specimens
were used as adjunctive diagnostic specimens, and the results were described as cyto-cell
blocks[14].
Anatomopathological examinations of tissue samples obtained at thyroidectomy were car-
ried out according to the World Health Organization Guidelines, and the pathology reports
pertaining to these samples were considered the gold standard for the diagnosis of thyroid can-
cer. The pathology reports provided information regarding AJCC/UICC TNM staging and the
presence of invasion. The risk of recurrence was evaluated according to the ATA thyroid can-
cer guidelines[5,7].
Statistical analysis
The clinical, laboratory, ultrasonography and cytological data, which are reported as the
mean–standard deviation (SD) values, or as the median with percentiles 25 and 75 (continuous
variables), or as absolute numbers and percentages (categorical variables), were compared
using an unpaired Student’s t-test, Mann–Whitney U-test, or chi-square test, as appropriate.
The influence of clinical factors on the risk of thyroid cancer was investigated using binary
logistic regression analysis. The differences in the cancer rates between groups with deter-
mined TSH levels, considering ROC curve cutoff value, were calculated using odds ratios and
95 percent confidence intervals. Statistical analysis of the results was performed with SPSS soft-
ware (Statistical Package for Social Sciences) version 18.0.
Results
Patient characteristics
A total of 886 patients with thyroid nodules were consecutively evaluated. Of them, 234 were
excluded due to thyroid hormone replacement therapy and/or a previous diagnosis of thyroid
cancer, and 37 patients because they did not have available TSH measurement. Thus, 615
patients participated in the study. The mean of age of the participants was 55.9 ±14.7 years,
and 544 (88.5%) were female. Solitary nodules were noted in 226 patients (36.7%). As men-
tioned in the Materials and Methods section, two different assays were used to measure the
TSH levels and thyroid nodules
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TSH levels during the study period. Since the reference ranges were slightly different between
these assays, we have analyzed the patients separately (Fig 1). The median TSH in 422 patients
evaluated by CLIA was 1.48 μU/mL (P25: 0.93 and P75: 2.31) while the median TSH was
1.55 μU/mL in 193 patients analyzed by ECLIA, (P25: 0.95 and P75: 2.80). There was no
Fig 1. Flow chart of patients who met inclusion/exclusion criteria for the study population. CLIA, Chemiluminescent immunoassay; ECLIA,
electrochemiluminscent immunoassay.
https://doi.org/10.1371/journal.pone.0188123.g001
TSH levels and thyroid nodules
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significant differences in median TSH values (P = 0.32). Indeed, the correlation between the
two different TSH assays showed a strong correlation (r = 0.99). Forty-three out of 261
(16.5%) patients analyzed presented positivity to TPO-Ab.
All patients underwent US-FNBA and had their sample analyzed by cytologic and cell block
diagnostic testing. The combined cytological and cell block (cyto-cell) interpretations were as
follows: 5.7% (n = 35) unsatisfactory, 70.6% (n = 434) benign, 9.1% (n = 56) indeterminate,
8.1% (n = 50) follicular lesion and 6.5% (n = 40) malignant (Table 1). Surgery was indicated
for 170 patients with the following cyto-cell results: 7 nondiagnostic cyto-cell blocks, 30 inde-
terminate lesions, 43 follicular lesions, 36 malignant lesions and 54 benign lesions, based on
clinical (compressive symptoms, recent growing) and ultrasonographic characteristics (large
nodules, microcalcification, irregular margin). Final histological data were available for 160
patients, 113 of whom had benign lesions (70.6%), and 47 of whom had malignant lesions
(29.3.% of surgical cases and 7.6% of the sample). Of the subgroup evaluated by CLIA, 112
patients underwent surgery and 30 (26.8%) had malignant nodules while 48 out of 193 patients
analyzed by ECLIA were thyroidectomized and 17 (35.4%) had thyroid cancer. The character-
istics of all enrolled patients are shown in Table 1. The distribution of age, gender, and other
clinical features were similar between both TSH assay groups. However, the presence of micro-
calcification were higher in CLIA group (19 vs. 13.5%; P = 0.00) and the distribution of
cytological evaluation showed a higher prevalence of indeterminate category in ECLIA group
(6.6 vs. 14.5%; P<0.001).
TSH and thyroid cancer
In the group evaluated by CLIA, 91.7% of patients showed serum TSH levels within the normal
range; 23 patients (5.5%) presented TSH levels less than 0.35 μU/mL, and 12 (2.8%) had TSH
levels greater than 5.5 μU/mL. In patients analyzed by ECLIA, TSH was within the normal
range in 87%; 4 (2.1%) patients showed TSH levels less than 0.27 μU/mL and 21 patients
(10.9%) have TSH levels greater than 4.20 μU/mL.
Table 1. Clinical and oncology features of patients included in the study.
All Samples CLIA ECLIA P value
(N = 615) (N = 422) (N = 193)
Age (yr.) 55.9 ± 14.7 56.4 ± 14.0 54.9 ± 16.0 0.25
Female gender (%) 544 (88.5) 378 (89.6) 166 (86) 0.20
Family history of thyroid cancer (%) 37/602 (6.1) 29/409 (7.1) 8/193 (4.1) 0.16
Personal history of other neoplasia (%) 68/604 (11.3) 48/411 (11.7) 20/193 (10.4) 0.63
Exposure to radiation (%) 28/601 (4.7) 23/408 (5.6) 5/188 (2.7) 0.98
Serum TSH (μU/mL) 1.48 (0.93–2.31) 1.55 (0.95–2.80) 0.32
Solitary nodule (%) 226 (36.7) 155 (36.7) 71 (36.8) 0.99
Microcalcifications (%) 106/483 (21.9) 80/292 (19) 26(13.5) 0.00
FNA cyto-cell block (%) 0.00
I—Nondiagnostic 35 (5.7) 20 (4.7) 15 (7.8)
II—Benign 434 (70.6) 315 (74.6) 119 (61.7)
III—Indeterminate 56 (9.1) 28 (6.6) 28 (14.5)
IV—Follicular lesion 50 (8.1) 30 (7.1) 20 (10.4)
V/VI—Malignant 40 (6.5) 29 (6.9) 11 (5.7)
Values are the mean ± SD or median (P25-P75). CLIA, chemiluminescent immunoassay; ECLIA, electrochemiluminscent immunoassay. The TSH
reference range is 0.35–5.50μU/mL by CLIA and 0.27–4.20μUI/mL by ECLIA. Solitary nodules and microcalcifications were evaluated by ultrasonography.
https://doi.org/10.1371/journal.pone.0188123.t001
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Noteworthy, patients with thyroid cancer exhibited higher median TSH levels than patients
with benign nodules irrespectively of the assay methodology: 2.25 vs. 1.50 (CLIA;P = 0.04) and
2.33 vs. 1.27 (ECLIA; P = 0.03) (Fig 2;Table 2). Moreover, a family history of thyroid cancer,
solitary nodules and the presence of microcalcifications were associated with malignancy
(Table 2). Further analysis using binary logistic regression identified elevated TSH levels, a
family history of thyroid cancer, the presence of microcalcifications and solitary nodule on
ultrasonography as independent risk factors for malignancy in patients with thyroid nodules.
There were no differences in age, gender, non-thyroid neoplasia history, presence of TPO-Ab
positivity or previous radiation exposure history between patients with benign nodules and
those with thyroid cancer.
To further explore the potential role of TSH levels as a predictor of thyroid cancer, we sub-
divided the sample into quartiles in accordance with the TSH level distribution of the study
(0.93, 0.94–1.48, 1.49–2.31 and2.32 μU/mL for CLIA and0.95, 0.96–1.55, 1.56–2.80 and
2.81 μU/mL ECLIA). Interestingly, we observed that the frequencies of malignancy in each
TSH quartile varies in accordance with TSH levels, for both assays (P = 0.02 and P = 0.04;
respectively, Fig 3). For CLIA group, the prevalence of malignancy in patients with TSH levels
in the first quartile (0.93 μU/mL) was 14.3%, while those in the upper quartile (2.32 μU/
mL) exhibited a cancer prevalence of 48.3% (OR 5.6; CI 1.35–23.2)(P = 0,01). The prevalence
of malignancy in patients evaluated by ECLIA with TSH levels in the first quartile (0.95 μU/
mL) was 23%, while those in the upper quartile (2.81 μU/mL) exhibited a cancer prevalence
of 64% (OR 5.83; CI 1.00–34.6)(P = 0,04). Of note, even within normal range of TSH, there
was a significantly increased risk of thyroid cancer as TSH increased.
We subsequently performed ROC curve analysis to identify the best TSH cutoff for predict-
ing malignancy. Remarkable, the TSH value of 2.26μU/mL was identified to both assays. Then,
we perform additional analyses using TSH levels as a categorical variable, the prevalence of
malignancy was higher in those patients with TSH levels >2.26 μU/mL than in patients with
lower TSH levels (<2.26 μU/mL) (OR 3.87; CI 1.87–8.01)(P = 0.00). Similar results were
Fig 2. TSH level in malignant and benign thyroid nodules. CLIA, Chemiluminescent immunoassay; ECLIA, electrochemiluminscent immunoassay.
Box plot illustrating the median TSH level and the TSH level quartiles and ranges in malignant and benign thyroid nodules for CLIA(A) and ECLIA (B).
Patients with thyroid cancer exhibited higher median TSH levels than patients with benign nodules for both methodology. P = 0.04 (A) and P = 0.03 (B).
https://doi.org/10.1371/journal.pone.0188123.g002
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obtained when only patients with normal TSH levels were analyzed (OR 3.42 CI 1.62–7.24)
(P = 0.00).
Among the 47 patients with thyroid cancer, three cases harbor medullary thyroid carci-
noma and 44 differentiated thyroid carcinoma (DTC). Among patients with DTC, 11 cases
were microcarcinoma (25.0%). There were no differences in prevalence of TSH >2.26 μU/mL
or distribution of TSH quartile between patients with or without microcarcinoma.
Discussion
In the present prospective study, we demonstrated that patients with malignant thyroid
nodules presented higher serum TSH levels than patients with benign nodules.
Table 2. Characteristics of patients with benign and malignant nodules.
Malignant nodule Benign nodule P value
(N = 47) (N = 113)
Age (yr.) 47.9 ± 13.6 50.9 ± 14.8 0.24
Male gender (%) 10 (21.3) 12 (10.6) 0.07
Family history of thyroid cancer (%) 7 (14.9) 5 (4.4) 0.03*
Personal history of other neoplasia (%) 4 (8.5) 8 (7.1) 0.79
Exposure to radiation (%) 2 (4.2) 4 (3.5) 0.84
Serum TSH (μU/mL)
CLIA 2.25 (1.12–4.07) 1.50 (0.99–2.17) 0.04
ECLIA 2.33 (1.30–3.06) 1.25 (0.79–2.10) 0.03
Microcalcifications (%) 21 (44.7) 16 (14.2) 0.00*
Solitary nodule (%) 26 (55.3) 42 (37.2) 0.03*
TPO-Ab positively (%) 4/22 (18.2) 6/55 (10.9) 0.39
Values are the mean ± sd or median (P25-P75). CLIA, chemiluminescent immunoassay; ECLIA, electrochemiluminscent immunoassay.The TSH reference
range is 0.35–5.50μU/mL by chemiluminescent and 0.27–4.20μU/mL by electrochemiluminscent. Solitary nodules and microcalcifications were evaluated
by ultrasonography (during US-FNA).
*Independent variable by binary logistic regression.
https://doi.org/10.1371/journal.pone.0188123.t002
Fig 3. Frequencies of malignant and benign nodules according to TSH quartile. CLIA, Chemiluminescent immunoassay; ECLIA,
electrochemiluminscent immunoassay. Frequencies of malignant (dashed bars) and benign (white bars) nodules according to TSH quartile for CLIA(A)
and ECLIA (B). A significant increase in the prevalence of malignancy was noted in higher TSH quartiles. P<0.01.
https://doi.org/10.1371/journal.pone.0188123.g003
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Accordingly, the prevalence of malignancy was higher in subjects with TSH levels >2.26
μU/mL, as defined via ROC curve analyses. Remarkably, additional analyses using TSH
levels as a categorical variable show that the risk of malignancy was higher in patients
with TSH levels in upper quartile as compared with patients with lower TSH levels in two
different methodologies.
TSH is a major thyroid cell growth factor, while TSH signaling pathway activation may be
required for the expression of other growth factors, receptors, and proto-oncogenes[28–30].
Accordingly, TSH suppression is an important therapeutic tool of clinical thyroid cancer man-
agement[5,7]. In the last years, several studies have addressed the role of TSH as a predictor of
thyroid nodule malignancy but the results are still open to discussion. Here, we have demon-
strated that patients with higher TSH levels have increased risk for malignancy. Remarkable,
as TSH quartiles increased, the likelihood of malignancy rose, and the odds ratio of thyroid
cancer in patients with TSH levels in the upper quartile was 5-fold higher than in those patients
with TSH levels in the first quartile (Fig 3). Similar results were observed using the ROC analy-
ses to define the TSH levels. Our observations are in agreement with previous studies [21–25]
although contrast with the data from the EPIC study[26]. Noteworthy, however, the EPIC was
a case-control study that includes only cancer-free subjects which might be a limiting when
compared with our study.
Despite the consistent association between higher TSH levels and malignant nodules shown
in most series, including this one, an optimal TSH cutoff value for predicting the risk of cancer
has not been yet identified. Indeed, the lack of previous studies validating nomograms or equa-
tions intended to determine an optimal TSH cutoff value has limited the use of serum TSH lev-
els as a malignancy predictor. Here, we found the TSH cutoff value (2.26 μU/mL) using the
best point of a ROC curve for the two different TSH assays used during the study period. Some
authors have suggested that while no consensus exists regarding a TSH cutoff value, it may be
practical to preferentially perform US-FNAB in nodules less than 1.5 or 2.0 cm exhibiting pat-
terns arousing low or very low suspicion for malignancy on ultrasonography[2,25]. Haymart
et al. suggested TSH may play a key role in optimizing surgical interventions when aspirates
are suspicious for malignancy[23]. These recommendations might support an adjunctive role
for TSH levels when evaluating thyroid nodules.
This study has several strengths, as it included a large number of patients with thyroid nod-
ules who were evaluated at a single institution and did not exclude patients with abnormal
TSH levels, which enhances the external validity of its findings and increases the clinical appli-
cability of its data. Also, two TSH methodologies were analyzed with consistent results. Thus,
the results presented here may have important clinical implications, since its indicate that TSH
levels may help on the diagnosis strategy, in conjunction with clinical, ultrasonographic and
cytological features. However, as noted above, TSH should not be used for diagnostic deci-
sion-making in isolation. Also, although we demonstrated a prospective study data, the design
of our study was not delineated for evaluate the TSH as a causative role in thyroid cancer path-
ogenesis. In this view, we do not recommend screening for thyroid cancer in patients with
chronic TSH elevations nor suppressive treatment for subclinical hypothyroidism and for
benign nodular disease.
Conclusions
Higher serum TSH levels are associated with an increased risk of thyroid cancer in patients
with thyroid nodules. The use of TSH as an adjunctive diagnostic test for stratifying the risk of
malignancy associated with thyroid nodules may have value to decision-making on diagnostic
approaches.
TSH levels and thyroid nodules
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